Comparison of the protective effects of truncated bFGF and native bFGF against murine lung carcinoma

International Journal of Molecular Medicine

Volumn 28, Issue 1, 2011, Pages 3-8

  Luo, Zichao ^a,b   Peng, Xinyun ^c   Shi, Huashan ^a   Gong, Changyang ^a   Qian, Zhiyong ^a   Yang, Li ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Angiogenesis; Anti tumor; Basic fibroblast growth factor; Truncated basic fibroblast growth factor

Indexed keywords

ADJUVANT; BASIC FIBROBLAST GROWTH FACTOR; MACROGOL; POLYCAPROLACTONE; TRUNCATED BASIC FIBROBLAST GROWTH FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FIBROBLAST; HYDROGEL; IMMUNE RESPONSE; IMMUNIZATION; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

ANIMALS; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; HYDROGEL; IMMUNOTHERAPY; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; NIH 3T3 CELLS; POLYESTERS; POLYETHYLENE GLYCOLS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECOMBINANT PROTEINS;

EID: 79955876768     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.676     Document Type: Article

References (41)

1. Javerzat S, Auguste P and Bikfalvi A: The role of fibroblast growth factors in vascular development. Trends Mol Med 8: 483-489, 2002.
2. Delrieu I: The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an insight into an intracrine mechanism. FEBSLett 468: 6-10, 2000.
3. Johnson DE, Lee PL, Lu J and Williams LT: Diverse forms of a receptor for acidic and basic fibroblast growth factors. Mol Cell Biol 10: 4728-4736, 1990.
4. Basilico C and Moscatelli D: The FGF family of growth factors and oncogenes. Adv Cancer Res 59: 115-165, 1992.
5. Werner S: Keratinocyte growth factor: a unique player in epithelial repair processes. Cytokine Growth Factor Rev 9: 153-165, 1998.
6. Bikfalvi A, Klein S, Pintccci G and Rifkin DB: Biological roles of fibroblast growth factor-2. Endocr Rev 18: 26-45, 1997. (Pubitemid 27076454)
7. Coleman AB: Positive and negative regulation of cellular sensitivity to anti-cancer drugs by FGF-2. Drug Resist Updat 6: 85-94, 2003.
8. Montesano R, Vassalli JD, Baird A, Guillemin R and Orci L: Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 83: 7297-7301, 1986. (Pubitemid 16000508)
9. Folkman J and Klagsbrun M: Angiogenic factors. Science 235: 442-447, 1987. (Pubitemid 17009577)
10. Risau W: Mechanisms of angiogenesis. Nature 386: 671-674, 1997.
11. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
12. Makrilia N, Lappa T, Xyla V, Nikolaidis I and Syrigos K: The role of angiogenesis in solid tumours: an overview. Eur J Intern Med 20: 663-671, 2009.
13. Thomas KA: Fibroblast growth factors. FASEB J 1: 434-440, 1987.
14. Gomm JJ, Smith J, Ryall GK, Baillie R, Turnbull L and Coombes RC: Localization of basic fibroblast growth factor and transforming growth factor beta 1 in the human mammary gland. Cancer Res 51: 4685-4692, 1991.
15. Ke Y, Fernig DG, Wilkinson MC, et al: The expression of basic fibroblast growth factor and its receptor in cell lines derived from normal human mammary gland and a benign mammary lesion. J Cell Sci 106: 135-143, 1993. (Pubitemid 23286785)
16. Rifkin DB and Moscatelli D: Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 109: 1-6, 1989. (Pubitemid 19180114)
17. Zhang XP, Yang L, Shi HS, et al: An N-, C-terminally truncated basic fibroblast growth factor and LPD (liposome-polycation-DNA) complexes elicits a protective immune response against murine colon carcinoma. Cancer Biol Ther 10: 1-6, 2010.
18. Plum SM, Holaday JW, Ruiz A, Madsen JW, Fogler WE and Fortier AH: Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine 19: 1294-1303, 2000. (Pubitemid 32008298)
19. Proceedings of a conference. Bergen, Norway, June 18-21, 1996. Modulation of the immune response to vaccine antigens. Dev Biol Stand 92: 1-372, 1998.
20. Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ and Narasimhan B: Vaccine adjuvants: current challenges and future approaches. J Pharm Sci 98: 1278-1316, 2009.
21. O'Hagan DT and Valiante NM: Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2: 727-735, 2003. (Pubitemid 37361788)
22. Jeong B, Bae YH, Lee DSand Kim SW: Biodegradable block copolymers as injectable drug-delivery systems. Nature 388: 860-862, 1997. (Pubitemid 27377054)
23. Miyata T, Asami N and Uragami T: A reversibly antigen-responsive hydrogel. Nature 399: 766-769, 1999.
24. Casadei MA, Pitarresi G, Calabrese R, Paolicelli P and Giammona G: Biodegradable and pH-sensitive hydrogels for potential colon-specific drug delivery: characterization and in vitro release studies. Biomacromolecules 9: 43-49, 2008. (Pubitemid 351201580)
25. Gong C, Shi S, Wu L, et al: Biodegradable in situ gel-forming controlled drug delivery system based on thermosensitive PCL-PEG-PCL hydrogel. Part 2: sol-gel-sol transition and drug delivery behavior. Acta Biomater 5: 3358-3370, 2009.
26. Gou ML, Huang MJ, Qian ZY, et al: Preparation of anionic poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) copolymeric nanoparticles as basic protein antigen carrier. Growth Factors 25: 202-208, 2007. (Pubitemid 350214968)
27. Chen X, Wang X, Wang Y, et al: Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release 145: 17-25, 2010.
28. Gong CY, Shi Peng XY, et al: Biodegradable thermosensitive injectable PEG-PCL-PEG hydrogel for bFGF antigen delivery to improve humoral immunity. Growth Factors 27: 377-383, 2009.
29. Hoffmann J, Schirner M, Menrad A and Schneider MR: A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res 57: 3847-3851, 1997. (Pubitemid 27381234)
30. Liu JY, Wei YQ, Yang L, et al: Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 102: 1815-1823, 2003.
31. Coleman AB, Metz MZ, Donohue CA, Schwarz RE and Kane SE: Chemosensitization by fibroblast growth factor-2 is not dependent upon proliferation, S-phase accumulation, or p53 status. Biochem Pharmacol 64: 1111-1123, 2002. (Pubitemid 35247818)
32. Macias D, Ganan Y, Ros MA and Hurle JM: In vivo inhibition of programmed cell death by local administration of FGF-2 and FGF-4 in the interdigital areas of the embryonic chick leg bud. Anat Embryol (Berl) 193: 533-541, 1996.
33. Yokoyama Y, Ozawa S, Seyama et al: Enhancement of apoptosis in developing chick neural retina cells by basic fibroblast growth factor. J Neurochem 68: 2212-2215, 1997. (Pubitemid 27176160)
34. Schwartz SM and Liaw L: Growth control and morphogenesis in the development and pathology of arteries. J Cardiovasc Pharmacol 21 (Suppl. 1): S31-S49, 1993. (Pubitemid 23069754)
35. Dow JK and deVere White RW: Fibroblast growth factor 2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology 55: 800-806, 2000. (Pubitemid 30330774)
36. Giavazzi R, Giuliani R, Coltrini D, et al: Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors. Cancer Res 61: 309-317, 2001. (Pubitemid 32095732)
37. Tsunoda S, Nakamura T, Sakurai H and Saiki I: Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization. Cancer Sci 98: 541-548, 2007. (Pubitemid 46562745)
38. Hori A, Sasada R, Matsutani E, et al: Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 51: 6180-6184, 1991.
39. Ribatti D, Vacca A, Rusnati M and Presta M: The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine Growth Factor Rev 18: 327-334, 2007. (Pubitemid 46891290)
40. Davidson JM, Klagsbrun M, Hill KE, et al: Accelerated wound repair, cell proliferation, and collagen accumulation are produced by a cartilage-derived growth factor. J Cell Biol 100: 1219-1227, 1985. (Pubitemid 15093475)
41. Hayek A, Culler FL, Beattie GM, Lopez AD, Cuevas P and Baird A, et al: An in vivo model for study of the angiogenic effects of basic fibroblast growth factor. Biochem Biophys Res Commun 147: 876-880, 1987. (Pubitemid 18007026)